Ustekinumab Is Superior to TNF Inhibitor Treatment in Resolving Enthesitis in Psa Patients with Active Enthesitis-Results from the Enthesial Clearance in Psoriatic Arthritis Study

Guilhon de Araujo E, Englbrecht M, Höpken S, Finzel S, Hueber A, Rech J, Schett G (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Arthritis and Rheumatology Wiley

Book Volume: 69

Authors with CRIS profile

Elizabeth Guilhon de Araujo Professur für Rheumatologie und Klinische Immunologie Matthias Englbrecht Lehrstuhl für Innere Medizin III Sabrina Höpken Lehrstuhl für Innere Medizin III Axel Hueber Department of Medicine 3 – Rheumatology and Immunology Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

Universitätsklinikum Freiburg DE Germany (DE)

How to cite

APA:

Guilhon de Araujo, E., Englbrecht, M., Höpken, S., Finzel, S., Hueber, A., Rech, J., & Schett, G. (2017). Ustekinumab Is Superior to TNF Inhibitor Treatment in Resolving Enthesitis in Psa Patients with Active Enthesitis-Results from the Enthesial Clearance in Psoriatic Arthritis Study.

MLA:

Guilhon de Araujo, Elizabeth, et al. "Ustekinumab Is Superior to TNF Inhibitor Treatment in Resolving Enthesitis in Psa Patients with Active Enthesitis-Results from the Enthesial Clearance in Psoriatic Arthritis Study." 2017.

BibTeX: Download